Miracell to Unveil Automated Stem Cell Extraction System at KIMES Busan 2022… “High Cell Survival Rate!”
Miracell (CEO Shin Hyun-soon) will showcase its automated stem cell extraction system at the 2022 Busan Medical Equipment Exhibition (KIMES BUSAN 2022), held at BEXCO Exhibition Center 2 in Busan from Friday, October 28th to Sunday, October 30th.
Miracell, which began its medical business in 1986, has dedicated itself to stem cell research and development since 2009, establishing itself as a stem cell specialist. Miracell’s biological drug manufacturing technology was directly registered as a new medical technology for treating conditions such as acute myocardial infarction (2014), critical limb ischemia (2013), and cartilage defects (2012),
and was certified by the Korea Food and Drug Administration (KFDA) and the Ministry of Health and Welfare in 2014.
This cutting-edge cell extraction system can extract large quantities of stem cells through selective isolation and concentration from blood and bone marrow.
The company has received the National Health Technology NET (No. 179) certification for its “Smart M-Cell 2” and has been selected by the government as a “National Innovative Company.”
It has been selected as a leading company in the healthcare and diagnostics sector. Recently registered with the FDA,
it has secured core technologies through GMP, ISO13485, ISO9001, and CE European Union standard certifications, and 22 patent applications for cell extraction technology.
The “Smart M-Cell 2” automated stem cell extraction system can selectively isolate, extract, and concentrate stem cells in just 17 minutes. Its key technology maximizes cell viability. It automatically adjusts the RPM and angle of the separation vessel and reduces friction between vessels to minimize cell damage. This bio-digital device utilizes a closed system that prevents air contact and is equipped with LEDs that stimulate cell activation.
Furthermore, because it utilizes autologous bone marrow or blood, it is safe from immune rejection and side effects.
It is used in hospitals and clinics nationwide, including university hospitals.
A Miracell representative explained, “We are leading the popularization of the stem cell market with Smart Mcell 2, a cutting-edge bio-regenerative medical device developed with our own technology based on years of accumulated expertise. We hope that KIMES BUSAN 2022 will lead to contracts with numerous hospitals and clinics, and provide an opportunity to widely publicize the effectiveness of Miracell’s unique technology and stem cell treatments both domestically and internationally.”
They continued, “Through membership in the Cellpia Global Platform (CGP), we have built an organic network with doctors and medical staff at hospitals and clinics in Korea and abroad, sharing specialized stem cell medical technology.
CGP provides education, technology transfer, medical system setup, and marketing to ensure safe stem cell regenerative medicine treatments for hospitals both domestically and internationally.”
Meanwhile, KIMES BUSAN 2022, a regional medical industry exhibition centered around Busan, encompassing Daegu, Ulsan, North Gyeongsang Province, and South Gyeongsang Province, provides an opportunity to experience next-generation medical devices and healthcare products tailored to the future healthcare market. With the consumption and demand for smartphone healthcare content and smart wearable devices rapidly increasing and competition among related companies intensifying, KIMES BUSAN 2022 will showcase and introduce diverse forms of smart healthcare products and services evolving through big data, the Internet of Things (IoT), biotechnology (BT), and information and communications technology (ICT).
Source: AVING (http://kr.aving.net)